# Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb)

> **NCT05411575** · PHASE2 · WITHDRAWN · sponsor: **4Living Biotech**

## Conditions studied

- COVID-19 Acute Respiratory Distress Syndrome
- COVID-19

## Interventions

- **DRUG:** Plerixafor 20 MG/ML [Mozobil]
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05411575
- **Lead sponsor:** 4Living Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-07-19
- **Primary completion:** 2022-10
- **Final completion:** 2022-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No participants Enrolled
- **Last updated:** 2023-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05411575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05411575, "Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05411575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*